Serious reporting on the science of aging, peptides, hormonal health, and evidence-based interventions for a longer healthspan.
The original CRISPR-Cas9 approach made large cuts in DNA. Newer approaches — base editing and prime editing — offer more precise molecular changes with fewer off-target effects. What the technical differences actually mean for therapeutic applications.
A synthetic pentadecapeptide originally isolated from human gastric juice has become the most-discussed recovery compound in the peptide community. What the actual clinical evidence shows, what the marketing overstates, and what consumers need to know about sourcing.
The cardiovascular training landscape has been transformed by Zone 2 discussions in recent years. What the underlying physiology actually supports, how to structure aging-adult cardiovascular training practically, and what results to expect over meaningful time horizons.
The nootropics and cognitive enhancement industry has grown substantially without commensurate growth in supporting evidence. What actually improves cognitive function in aging adults, ranked honestly by evidence strength, and what interventions consumers are wasting money on.
Casgevy's approval for sickle cell disease was hailed as the arrival of gene editing medicine. Two years of real-world use has generated meaningful data on efficacy, access barriers, and the practical realities of delivering revolutionary treatments at scale.
Two years after the first FDA-approved CRISPR therapy for sickle cell disease, the gene editing revolution has entered its practical phase. What's actually been treated, what's in trials, and what the honest timeline looks like for broader access.
The pricing of gene therapies has become one of the most contentious topics in healthcare economics. What the actual manufacturing cost is, what the pricing rationale involves, and whether current models will produce broad patient access or entrench a new tier of ultra-expensive medicine.
Gut microbiome science has produced impressive research and a substantial commercial ecosystem of dubious interventions. What the evidence actually supports for consumers seeking meaningful gut health improvement, honestly ranked.
A pair of secretagogue peptides has become the mainstream alternative to synthetic HGH injection. What the actual pharmacology does, why the combination outperforms either alone, and what consumers should know about the safety profile that made these compounds popular.
The single biggest determinant of peptide protocol success is not dosing subtlety or protocol design — it's whether the compound you inject is what the label claims. A practical framework for navigating the peptide sourcing landscape without becoming the case study in why quality control matters.
As retatrutide moves from investigational to widely accessed, users are combining it with BPC-157, ipamorelin, and other peptides for compound effects. The pharmacology of stacking, what evidence supports it, and what risks the stack approach introduces.
Sleep quality declines with age even in healthy adults. The wellness industry has responded with an ocean of dubious interventions. What the actual sleep science supports, and what a realistic protocol for adult sleep optimization looks like.
While the wellness industry markets research-chemical peptides, one FDA-approved growth hormone releasing factor has demonstrated meaningful visceral fat reduction in controlled trials. What the actual data shows, why it's underused, and who should consider it.
The wellness industry markets testosterone optimization as requiring pharmaceutical intervention. In fact, lifestyle interventions can meaningfully affect endogenous testosterone production for most men with age-related decline. What actually works, ranked honestly by evidence and impact.
Partial cellular reprogramming using Yamanaka factors has produced striking results in mouse studies — reversal of aging markers, extended lifespan, restored tissue function. What the honest evidence shows about whether this translates to human anti-aging therapy.